Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

The Commercial Sickness Fund - KKH (hereinafter KKH) aims to conclude rebate agreements under Section 130a, paragraph 8, SGB V, with all suitable pharmaceutical companies for the active substance(s) within the framework of a so-called "Open-House procedure". By specifying uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a rebate agreement under Section 130a, paragraph 8, SGB V, for the active substance(s) specified in the invitation to tender. Interested pharmaceutical companies can request the participation documents and the contract from the contact address ([email protected]).